Key result
Beta-blockade partially reverses harmful effects of high adrenergic tone in heart failure.
Why the study?
Congestive heart failure remains a major health problem with high mortality despite existing therapies, necessitating new treatment approaches.
Do beta-blocking agents improve outcomes in patients with congestive heart failure?
Do beta-blocking agents improve outcomes in patients with congestive heart failure?
This review highlights the pathophysiological rationale and clinical data supporting the use of beta-blockers to counteract deleterious adrenergic tone in heart failure.
Answers are grounded in this paper and cite their sources.
Beta-blockade may benefit heart failure beyond standard therapy; leaves open confirmation in definitive randomized trials.
Despite therapy with diuretics, digoxin, and angiotensin-converting enzyme inhibitors, congestive heart failure remains an important health problem with high mortality, and it is clear that new treatments for heart failure are needed. Evidence from basic research, animal studies, and clinical human trials indicates that high adrenergic tone in patients with heart failure is deleterious; furthermore, the deleterious effects are partially reversible with beta-adrenergic blockade. This article reviews the recent developments in our understanding of the pathophysiology of heart failure and the recent data concerning the treatment of heart failure with beta-blocking agents.
No takes yet. Share an insight, caveat, or question.
Slatton et al. (1996) conducted a review in congestive heart failure. beta-blocking agents was evaluated. Beta-adrenergic blockade partially reverses the deleterious effects of high adrenergic tone in patients with congestive heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: